JP2014506913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506913A5 JP2014506913A5 JP2013555935A JP2013555935A JP2014506913A5 JP 2014506913 A5 JP2014506913 A5 JP 2014506913A5 JP 2013555935 A JP2013555935 A JP 2013555935A JP 2013555935 A JP2013555935 A JP 2013555935A JP 2014506913 A5 JP2014506913 A5 JP 2014506913A5
- Authority
- JP
- Japan
- Prior art keywords
- deoxyuridine
- fluoro
- phosphate
- naphthyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1103582.1 | 2011-03-01 | ||
| GBGB1103582.1A GB201103582D0 (enExample) | 2011-03-01 | 2011-03-01 | |
| GB1105660.3 | 2011-04-01 | ||
| GBGB1105660.3A GB201105660D0 (en) | 2011-04-01 | 2011-04-01 | Chemical compounds |
| PCT/GB2012/050457 WO2012117246A1 (en) | 2011-03-01 | 2012-02-29 | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506913A JP2014506913A (ja) | 2014-03-20 |
| JP2014506913A5 true JP2014506913A5 (enExample) | 2015-04-16 |
| JP5978232B2 JP5978232B2 (ja) | 2016-08-24 |
Family
ID=45841523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555935A Active JP5978232B2 (ja) | 2011-03-01 | 2012-02-29 | がん治療での使用のための５−フルオロ−２’−デオキシウリジンのホスホラミダート誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8933053B2 (enExample) |
| EP (4) | EP3447061B1 (enExample) |
| JP (1) | JP5978232B2 (enExample) |
| KR (1) | KR101885940B1 (enExample) |
| CN (2) | CN103403013B (enExample) |
| AU (1) | AU2012223012C1 (enExample) |
| BR (1) | BR112013021986B1 (enExample) |
| CA (1) | CA2828326C (enExample) |
| CL (1) | CL2013002517A1 (enExample) |
| CY (2) | CY1117445T1 (enExample) |
| DK (3) | DK3031812T3 (enExample) |
| ES (4) | ES2569185T3 (enExample) |
| HR (2) | HRP20211967T1 (enExample) |
| HU (2) | HUE029022T2 (enExample) |
| IL (1) | IL228169A (enExample) |
| LT (1) | LT3447061T (enExample) |
| MX (1) | MX339822B (enExample) |
| NZ (1) | NZ615270A (enExample) |
| PH (2) | PH12013501723A1 (enExample) |
| PL (3) | PL2681227T3 (enExample) |
| PT (2) | PT3447061T (enExample) |
| RS (2) | RS54776B1 (enExample) |
| RU (1) | RU2614406C2 (enExample) |
| SG (1) | SG192841A1 (enExample) |
| SI (2) | SI3447061T1 (enExample) |
| SM (2) | SMT202100715T1 (enExample) |
| WO (1) | WO2012117246A1 (enExample) |
| ZA (2) | ZA201306468B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| ES2569185T3 (es) | 2011-03-01 | 2016-05-09 | Nucana Biomed Limited | Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer |
| AU2013346515B2 (en) * | 2012-11-16 | 2017-05-25 | NuCana plc | Process for preparing nucleoside prodrugs |
| WO2015013352A2 (en) * | 2013-07-25 | 2015-01-29 | Patel Hasmukh B | Nucleoside phosphoramidates and phosphoramidites |
| CN104447923B (zh) * | 2013-09-23 | 2018-03-30 | 中国药科大学 | 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途 |
| RU2553996C1 (ru) * | 2013-11-27 | 2015-06-20 | Андрей Александрович Иващенко | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| AU2015265607A1 (en) * | 2014-05-28 | 2016-11-17 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| CN105153257B (zh) * | 2014-06-12 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 索非布韦的制备方法 |
| RS60968B1 (sr) | 2014-06-25 | 2020-11-30 | NuCana plc | Prolekovi gemcitabina |
| PL225283B1 (pl) | 2014-07-24 | 2017-03-31 | Univ Im Adama Mickiewicza W Poznaniu | Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie |
| HRP20191461T1 (hr) | 2014-11-28 | 2019-11-15 | NuCana plc | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
| FI3265102T3 (fi) | 2015-03-06 | 2025-10-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten |
| EP3303361A1 (en) * | 2015-05-27 | 2018-04-11 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of cancer |
| EP3377512A4 (en) * | 2015-11-16 | 2019-09-18 | Ichorion Therapeutics, Inc. | Nucleic Acid PRODRUGS |
| GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| EP3538124A4 (en) | 2016-11-13 | 2020-07-22 | Imagine Pharma | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA |
| US10899786B2 (en) | 2016-12-23 | 2021-01-26 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nucleoside phosphate compound and preparation method and use thereof |
| RU2644156C1 (ru) * | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| JP2020530035A (ja) | 2017-08-08 | 2020-10-15 | スン・ヤット−セン・ユニバーシティＳｕｎ Ｙａｔ−Ｓｅｎ Ｕｎｉｖｅｒｓｉｔｙ | 多剤耐性腫瘍を治療するための方法および組成物 |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| EP3763724A4 (en) * | 2018-03-09 | 2022-01-12 | Japan Science and Technology Agency | SS-MODIFIED PHOSPHORIC ACID COMPOUND PRECURSOR, SS-MODIFIED PHOSPHORIC ACID COMPOUND, RESPONSE INHIBITOR AND DRUG THEREOF, AND RESPONSE INHIBITION METHOD |
| CN110387226A (zh) * | 2018-04-20 | 2019-10-29 | 天津大学 | 一种用于检测肿瘤的荧光探针及用途 |
| WO2020111279A1 (ja) * | 2018-11-30 | 2020-06-04 | 国立大学法人 東京大学 | カルボキシペプチダーゼ活性検出用蛍光プローブ |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| CN110840907B (zh) * | 2019-08-16 | 2022-11-25 | 南京医科大学 | 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CA3189501A1 (en) * | 2020-08-31 | 2022-03-03 | Emory University | 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto |
| CN120584123A (zh) | 2022-12-07 | 2025-09-02 | 努卡那有限公司 | 核苷衍生物nuc-3373的合成 |
| WO2026151964A1 (en) | 2025-01-10 | 2026-07-16 | Atea Pharmaceuticals, Inc. | Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US1002239A (en) | 1902-04-11 | 1911-09-05 | Stromberg Carlson Telephone | Telephone system. |
| US2945038A (en) | 1956-09-26 | 1960-07-12 | Hoffmann La Roche | 5-fluorocytosine and preparation thereof |
| US3201387A (en) | 1963-09-18 | 1965-08-17 | Heidelberger Charles | 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same |
| US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
| DD279248A1 (de) | 1989-01-01 | 1990-05-30 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| RU2197964C2 (ru) * | 1995-04-12 | 2003-02-10 | Дзе Проктер Энд Гэмбл Компани | Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| ES2172303T3 (es) * | 1998-01-23 | 2002-09-16 | Newbiotics Inc | Agentes terapeuticos obtenidos por catalisis enzimatica. |
| HK1053126A1 (zh) | 1999-07-22 | 2003-10-10 | 新生物生物公司 | 酶催化的治疗活化 |
| DE10109657A1 (de) | 2001-02-28 | 2002-09-05 | Menarini Ricerche Spa | Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin |
| EP1404694A1 (en) | 2001-06-21 | 2004-04-07 | Glaxo Group Limited | Nucleoside compounds in hcv |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| EP1827460A4 (en) | 2004-12-09 | 2012-03-14 | Univ Minnesota | NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| CN101287472B (zh) | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| WO2007056596A2 (en) | 2005-11-09 | 2007-05-18 | Wayne State University | Phosphoramidate derivatives of fau |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| CN101922935B (zh) | 2010-07-16 | 2012-07-18 | 北京大学 | 一种最小互易结构干涉型全光纤陀螺仪 |
| EA025311B1 (ru) | 2010-07-19 | 2016-12-30 | Гайлид Сайэнсиз, Инк. | Способы получения диастереомерно чистых фосфорамидатных пролекарств |
| US20120070411A1 (en) | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012040127A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012048013A2 (en) | 2010-10-06 | 2012-04-12 | Inhibitex, Inc. | Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| US9346811B2 (en) | 2011-03-01 | 2016-05-24 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| ES2569185T3 (es) * | 2011-03-01 | 2016-05-09 | Nucana Biomed Limited | Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer |
| EA033046B1 (ru) | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| HRP20191461T1 (hr) | 2014-11-28 | 2019-11-15 | NuCana plc | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
| CN107835687A (zh) | 2015-05-14 | 2018-03-23 | 努卡那有限公司 | 癌症治疗 |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
-
2012
- 2012-02-29 ES ES12709146.0T patent/ES2569185T3/es active Active
- 2012-02-29 EP EP18178715.1A patent/EP3447061B1/en active Active
- 2012-02-29 ES ES18178715T patent/ES2903097T3/es active Active
- 2012-02-29 NZ NZ615270A patent/NZ615270A/en unknown
- 2012-02-29 US US14/000,682 patent/US8933053B2/en active Active
- 2012-02-29 LT LTEP18178715.1T patent/LT3447061T/lt unknown
- 2012-02-29 RS RS20160211A patent/RS54776B1/sr unknown
- 2012-02-29 HU HUE12709146A patent/HUE029022T2/en unknown
- 2012-02-29 DK DK16150494.9T patent/DK3031812T3/en active
- 2012-02-29 PH PH1/2013/501723A patent/PH12013501723A1/en unknown
- 2012-02-29 KR KR1020137025749A patent/KR101885940B1/ko active Active
- 2012-02-29 AU AU2012223012A patent/AU2012223012C1/en active Active
- 2012-02-29 EP EP21209926.1A patent/EP4023299B1/en active Active
- 2012-02-29 RS RS20211549A patent/RS62721B1/sr unknown
- 2012-02-29 EP EP16150494.9A patent/EP3031812B1/en active Active
- 2012-02-29 SG SG2013062823A patent/SG192841A1/en unknown
- 2012-02-29 EP EP12709146.0A patent/EP2681227B1/en active Active
- 2012-02-29 DK DK12709146.0T patent/DK2681227T3/da active
- 2012-02-29 DK DK18178715.1T patent/DK3447061T3/da active
- 2012-02-29 JP JP2013555935A patent/JP5978232B2/ja active Active
- 2012-02-29 HU HUE18178715A patent/HUE060127T2/hu unknown
- 2012-02-29 HR HRP20211967TT patent/HRP20211967T1/hr unknown
- 2012-02-29 PL PL12709146T patent/PL2681227T3/pl unknown
- 2012-02-29 RU RU2013143862A patent/RU2614406C2/ru active
- 2012-02-29 PL PL16150494T patent/PL3031812T3/pl unknown
- 2012-02-29 PT PT181787151T patent/PT3447061T/pt unknown
- 2012-02-29 BR BR112013021986-6A patent/BR112013021986B1/pt active IP Right Grant
- 2012-02-29 ES ES21209926T patent/ES3039965T3/es active Active
- 2012-02-29 CA CA2828326A patent/CA2828326C/en active Active
- 2012-02-29 PL PL18178715T patent/PL3447061T3/pl unknown
- 2012-02-29 HR HRP20160346TT patent/HRP20160346T1/hr unknown
- 2012-02-29 SI SI201231972T patent/SI3447061T1/sl unknown
- 2012-02-29 CN CN201280010761.4A patent/CN103403013B/zh active Active
- 2012-02-29 PT PT16150494T patent/PT3031812T/pt unknown
- 2012-02-29 WO PCT/GB2012/050457 patent/WO2012117246A1/en not_active Ceased
- 2012-02-29 SI SI201230488T patent/SI2681227T1/sl unknown
- 2012-02-29 ES ES16150494.9T patent/ES2686219T3/es active Active
- 2012-02-29 CN CN201510329656.2A patent/CN104974206B/zh active Active
- 2012-02-29 MX MX2013009815A patent/MX339822B/es active IP Right Grant
- 2012-02-29 SM SM20210715T patent/SMT202100715T1/it unknown
-
2013
- 2013-08-28 IL IL228169A patent/IL228169A/en active IP Right Grant
- 2013-08-30 CL CL2013002517A patent/CL2013002517A1/es unknown
- 2013-09-09 ZA ZA2013/06468A patent/ZA201306468B/en unknown
-
2014
- 2014-12-04 US US14/560,097 patent/US9221866B2/en active Active
- 2014-12-09 ZA ZA2014/09013A patent/ZA201409013B/en unknown
-
2015
- 2015-03-05 PH PH12015500485A patent/PH12015500485A1/en unknown
- 2015-11-17 US US14/943,555 patent/US9655915B2/en active Active
-
2016
- 2016-04-27 CY CY20161100360T patent/CY1117445T1/el unknown
- 2016-05-06 SM SM201600132T patent/SMT201600132B/it unknown
-
2017
- 2017-04-18 US US15/489,884 patent/US10022390B2/en active Active
-
2018
- 2018-06-28 US US16/021,103 patent/US10993957B2/en active Active
-
2021
- 2021-04-06 US US17/223,241 patent/US11559542B2/en active Active
- 2021-12-17 CY CY20211101114T patent/CY1124871T1/el unknown
-
2023
- 2023-01-11 US US18/095,937 patent/US11925658B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013143862A (ru) | Фосфороамидатные производные 5-фтор-2'-дезоксиуридина для применения для лечения рака | |
| US12098139B2 (en) | Chemokine receptor modulators and uses thereof | |
| US10604526B2 (en) | Chemokine receptor modulators and uses thereof | |
| US10946033B2 (en) | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | |
| US10246462B2 (en) | Chemokine receptor modulators and uses thereof | |
| US10011629B2 (en) | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
| JP2017036314A5 (enExample) | ||
| CN118834840A (zh) | 嵌合痘病毒组合物及其用途 | |
| CN107108683A (zh) | 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物 | |
| JP2014534269A5 (enExample) | ||
| CN114867351A (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| CN109843329A (zh) | 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法 | |
| JP2012522842A5 (enExample) | ||
| ES2908854T3 (es) | Método para producir un arenavirus antitumoral así como mutantes de arenavirus | |
| JP2014510699A5 (enExample) | ||
| US8952019B2 (en) | Methods of using selective chemotherapeutic agents for targeting tumor cells | |
| JP2009527463A5 (enExample) | ||
| CN102319247A (zh) | 一种靶向于mir-26a的抗肿瘤小分子化合物 | |
| US20250122208A1 (en) | Chemokine receptor modulators and uses thereof | |
| WO2015192052A1 (en) | Egfr targeting compounds and methods of use thereof | |
| CN101980713A (zh) | 含有胞嘧啶核苷衍生物与卡铂的抗肿瘤剂 |